RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
06 01 2021
Historique:
received: 14 07 2020
accepted: 22 12 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

The relevant role of long non-coding RNAs (lncRNAs) in cancer is currently a matter of increasing interest. Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor (2-5% of all thyroid cancer) derived from the parafollicular C-cells which secrete calcitonin. About 75% of all medullary thyroid cancers are believed to be sporadic medullary thyroid cancer (sMTC), whereas the remaining 25% correspond to inherited cancer syndromes known as Multiple Endocrine Neoplasia type 2 (MEN2). MEN2 syndrome, with autosomal dominant inheritance is caused by germline gain of function mutations in RET proto-oncogene. To date no lncRNA has been associated to MEN2 syndrome and only two articles have been published relating long non-coding RNA (lncRNA) to MTC: the first one linked MALAT1 with sMTC and, in the other, our group determined some new lncRNAs in a small group of sMTC cases in fresh tissue (RMST, FTX, IPW, PRNCR1, ADAMTS9-AS2 and RMRP). The aim of the current study is to validate such novel lncRNAs previously described by our group by using a larger cohort of patients, in order to discern their potential role in the disease. Here we have tested three up-regulated (RMST, FTX, IPW) and one down-regulated (RMRP) lncRNAs in our samples (formalin fixed paraffin embedded tissues from twenty-one MEN2 and ten sMTC patients) by RT-qPCR analysis. The preliminary results reinforce the potential role of RMST, FTX, IPW and RMRP in the pathogenesis of MTC.

Identifiants

pubmed: 33407723
doi: 10.1186/s13023-020-01665-5
pii: 10.1186/s13023-020-01665-5
pmc: PMC7789680
doi:

Substances chimiques

MAS1 protein, human 0
Proto-Oncogene Mas 0
RNA, Long Noncoding 0
Proto-Oncogene Proteins c-ret EC 2.7.10.1

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4

Références

Nat Genet. 2014 Jun;46(6):551-7
pubmed: 24816254
Onco Targets Ther. 2020 Mar 31;13:2677-2688
pubmed: 32280242
JAMA. 1996 Nov 20;276(19):1575-9
pubmed: 8918855
J Med Genet. 2000 Nov;37(11):817-27
pubmed: 11073534
Asian Pac J Cancer Prev. 2020 Feb 01;21(2):281-287
pubmed: 32102500
Front Immunol. 2019 Jul 16;10:1581
pubmed: 31379817
Rev Endocr Metab Disord. 2019 Jun;20(2):239-250
pubmed: 31065942
Med Clin (Barc). 2009 Jul 4;133(5):196-7
pubmed: 19268982
J Exp Clin Cancer Res. 2018 Nov 21;37(1):279
pubmed: 30463570
Int J Oncol. 2018 Aug;53(2):551-566
pubmed: 29845188
J Cell Physiol. 2020 Feb;235(2):1366-1373
pubmed: 31297834
J Clin Oncol. 1999 Jan;17(1):380-93
pubmed: 10458257
Gene Ther. 2018 Aug;25(5):321-330
pubmed: 29925853
Mol Diagn Ther. 2018 Feb;22(1):41-56
pubmed: 28986854
Int J Mol Med. 2006 Apr;17(4):575-81
pubmed: 16525712
J Pediatr Endocrinol Metab. 2019 Feb 25;32(2):159-165
pubmed: 30703060
Am J Hum Genet. 2005 Nov;77(5):795-806
pubmed: 16252239
Cancer Biol Ther. 2020 Apr 2;21(4):379-387
pubmed: 31920141
Sci Rep. 2019 Oct 7;9(1):14374
pubmed: 31591432
Nat Rev Cancer. 2013 Mar;13(3):184-99
pubmed: 23429735
Curr Opin Endocrinol Diabetes Obes. 2019 Oct;26(5):275-281
pubmed: 31385810
Endocr Pathol. 2019 Dec;30(4):262-269
pubmed: 31468286
Onco Targets Ther. 2018 Aug 21;11:5035-5043
pubmed: 30174441
World J Gastroenterol. 2019 Jan 14;25(2):220-232
pubmed: 30670911
Exp Mol Pathol. 2017 Oct;103(2):229-236
pubmed: 29107050
Biotech Histochem. 2018;93(5):373-386
pubmed: 30113239
J Clin Lab Anal. 2018 Mar;32(3):
pubmed: 28703321
Semin Cancer Biol. 2020 Dec;67(Pt 1):122-153
pubmed: 30914279
J Med Genet. 1999 Jan;36(1):68-70
pubmed: 9950371
Genes (Basel). 2019 Nov 08;10(11):
pubmed: 31717449
Onco Targets Ther. 2019 Sep 06;12:7307-7321
pubmed: 31564913
Hum Mutat. 1998;Suppl 1:S72-3
pubmed: 9452046
Thyroid. 2009 Dec;19(12):1343-9
pubmed: 20001717
J Med Genet. 2020 Jan;57(1):18-22
pubmed: 31413121
Clin Genet. 2002 Feb;61(2):146-51
pubmed: 11940090
Mol Ther. 2020 Jan 8;28(1):9-18
pubmed: 31636039
Comput Math Methods Med. 2020 Apr 23;2020:3651051
pubmed: 32377223
J Exp Clin Cancer Res. 2019 Jul 8;38(1):295
pubmed: 31287002

Auteurs

Berta Luzón-Toro (B)

Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain.
Centre for Biomedical Network Research on Rare Diseases CIBERER, Seville, Spain.

Leticia Villalba-Benito (L)

Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain.
Centre for Biomedical Network Research on Rare Diseases CIBERER, Seville, Spain.

Raquel María Fernández (RM)

Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain.
Centre for Biomedical Network Research on Rare Diseases CIBERER, Seville, Spain.

Ana Torroglosa (A)

Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain.
Centre for Biomedical Network Research on Rare Diseases CIBERER, Seville, Spain.

Guillermo Antiñolo (G)

Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain.
Centre for Biomedical Network Research on Rare Diseases CIBERER, Seville, Spain.

Salud Borrego (S)

Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC, University of Seville, Seville, Spain. salud.borrego.sspa@juntadeandalucia.es.
Centre for Biomedical Network Research on Rare Diseases CIBERER, Seville, Spain. salud.borrego.sspa@juntadeandalucia.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH